Financing ·
Ocugen reported a net loss of $0.07 per share for the quarter ended June 30, 2026, with operating expenses rising to…
OCGNOcugen, Inc.
Ocugen reported a net loss of $0.07 per share for the quarter ended June 30, 2026, with operating expenses rising to $17.9 million from $15.2 million in the prior year period. The company closed a $130.0 million convertible senior notes financing, generating approximately $112.5 million in net proceeds, which it used to fully retire its Avenue Capital loan and extend its cash runway into 2028. Cash reserves increased to $100.4 million as of June 30, 2026. Clinically, Ocugen received FDA clearance to initiate the Phase 3 ArMaDa trial for OCU410 in geographic atrophy and was granted RMAT designation for the same program. The company also signed a binding term sheet with Roots Pharmaceutical for an exclusive license of OCU400 in the MENA region, featuring up to $255 million in sales milestones. Ocugen appointed Mohamed Genead as Chief Medical Officer and Chris Clark as Head of Corporate Communications. Ocugen is a biotechnology company developing gene therapies for blindness diseases.